DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0302592 A1 Johnson Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20120302592A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0302592 A1 Johnson et al. (43) Pub. Date: Nov. 29, 2012 (54) TOPIRAMATE PLUS NALTREXONE FOR (60) Provisional application No. 60/898,527, filed on Jan. THE TREATMENT OF ADDICTIVE 31, 2007. DSORDERS (75) Inventors: Bankole A. Johnson, O O Charlottesville, VA (US); Nassima Publication Classification Ait-Daoud Tiouririne, (51) Int. Cl. Charlottesville, VA (US); Wendy J. A63L/485 (2006.01) Lynch, Charlottesville, VA (US) A6IP 25/36 (2006.01) (73) Assignee: University of Virginia Patent A6IP 25/34 (2006.01) Foundation, Charlottesville, VA A6IP 25/30 (2006.01) (US) A6IP 25/32 (2006.01) (21) Appl. No.: 13/569.465 (52) U.S. Cl. ........................................................ S14/282 (22) Filed: Aug. 8, 2012 Related U.S. Application Data 57 ABSTRACT (63) Continuation of application No. 12/525.320, filed on (57) Jul. 31, 2009, now abandoned, filed as application No. The present invention provides for the use of combinations of PCT/US2008/052628 on Jan. 31, 2008. drugs to treat addictive disorders. Patent Application Publication Nov. 29, 2012 Sheet 1 of 12 US 2012/0302592 A1 3 Drinks I EEEE Day 2 EEEE O EEEE Plac Ond 1 Ond 4 Ond 16 Plac Ond 1 Ond 4. Ond 16 Start of double blind End of study Placebo (Plac) gieron 1 ug/kg b.i.d. n Ondansetron 4 ug/kg I Ondansetron 16 ug/kg b.i.d. b.i.d. (Ond 4) (Ond 16) FIG. 1A Patent Application Publication Nov. 29, 2012 Sheet 2 of 12 US 2012/0302592 A1 Mean Drinks I Day 2 Plac Ond 1 Ond 4 Ond 16 Plac Ond 1 Ond 4 Ond 16 Start of double blind End of study Placebo (Plac) gieron 1 ug/kg b.i.d. n Ondansetron 4 pug/kg I Ondansetron 16 lug/kg b.i.d. b.i.d. (Ond 4) (Ond 16) F.G. 1B Patent Application Publication Nov. 29, 2012 Sheet 3 of 12 US 2012/0302592 A1 0.3 Mean 0.2 Log CDT 0.1 Ratio -0.0 -0.1 -0.2 -0.3 -0.4 Plac Ond 1 Ond 4 Ond 16 Ondansetron doses in lug/kg b.i.d. Placebo (Plac) Ondansetron 1 ug/kg b.i.d. (Ond 4) Ondansetron 4 ug/kg I Ondansetron 16 pug/kg b.i.d. b.i.d. (Ond 4) (Ond 16) FIG. 2A Patent Application Publication Nov. 29, 2012 Sheet 4 of 12 US 2012/0302592 A1 Mean 0.1 Log CDT -0.0 Ratio Plac Ond 1 Ond 4 Ond 16 Ondansetron doses in ug/kg b.i.d. Placebo (Plac) getonn 1 ug/kg b.i.d. Ondansetron 4 ug/kg I Ondansetron 16 ug/kg b.i.d. b.i.d. (Ond 4) (Ond 16) FIG. 2B Patent Application Publication Nov. 29, 2012 Sheet 5 of 12 US 2012/0302592 A1 6 O Group Mean -O-- 0.1 Naitrexone 4O -- 0.3 Naitrexone 0 Naitrexone 2O 3.0 Naitrexone O AS S) (S N) &S) Sy 1S (S) co & AS S AeS 28 & & & AS Time (10 minute time blocks) FIG. 3 Patent Application Publication Nov. 29, 2012 Sheet 6 of 12 US 2012/0302592 A1 1 O 9 Mean 8 drinks/ drinking 5 day 4 3 2 1. O O 1 2 3 4 5 6 7 8 Study Weeks Baseli a SCI116 Start of double-blind O Ondansetron 4 u g/kg b.i.d. + Naltrexone 25 mg b.i.d. group -O-Placebo group FIG. 4A Patent Application Publication Nov. 29, 2012 Sheet 7 of 12 US 2012/0302592 A1 12 11 1O Mean drinks/ drinking day O O 1. 2 3 4. 5 6 7 8 A A Study Weeks Baseline Start of double-blind O Ondansetron 4 u g/kg b.i.d. + Naltrexone 25 mg b.i.d. group -O-Placebo group FIG. 4B Patent Application Publication Nov. 29, 2012 Sheet 8 of 12 US 2012/0302592 A1 24 16 12 1 2 3 4 5 6 7 8 9 10 11 12 Week of Study A Placebo O 2.5 mg Rit a 5.0 mg Rit FIG.S Patent Application Publication Nov. 29, 2012 Sheet 9 of 12 US 2012/0302592 A1 Alcohol Dependent patients N=360 Early Onset Alcoholics late Onset Alcoholics (EOA) N=180 (LOA) N=180 Alcoholism onsets 25 years Alcoholism on Sct > 25 years a High family history of alcoholism "Less family history of alcoholism in 1st degree relatives in 1st degree relatives Antisocial behaviors and symptoms "Few antisocial bchaviors and Symptoms Cognitive Bchavioral Therapy Cognitive Behavioral Therapy Placcbo Ondansetron Ondansetron Ondansetron Ondansetron -- -- -- Placebo Naltrexone Placcbo Naltrexone Naltrexone Placcbo Naltrexone N=45 N=45 N=45 FIG. 6 Patent Application Publication Nov. 29, 2012 Sheet 10 of 12 US 2012/0302592 A1 N Study & years S. N N 0 1 2 3 4 5 6 7 8 9 10 Subject Enrolled Completed FIG. 7 Patent Application Publication Nov. 29, 2012 Sheet 11 of 12 US 2012/0302592 A1 Effect of Naltrexonel Topiramate on 2O Alcohol Consumption vehicle 5 Top 10 Top Nar Nairo Top 1 Nal -24 5 Top FG. 8 Patent Application Publication Nov. 29, 2012 Sheet 12 of 12 US 2012/0302592 A1 Eises to Frofia Cofi ef: S to hippoca. ERS N. Arcuatus 5HT3 receptors Š 3- endorphifts S&rester ST3 receptoE facilitate (ABA intereiros Bopanine s: Afferent from the Hippocampus to the N. Accinaens FIG. 9 US 2012/0302592 A1 Nov. 29, 2012 TOPIRAMATE PLUS NALTREXONE FOR development and maintenance of alcohol dependence. To THE TREATMENT OF ADDCTIVE date, most pharmacotherapy trials have focused on single DISORDERS pharmacological agents. However, because of the failure to find consistent results with these drug therapies, investigating CROSS REFERENCE TO RELATED the efficacy of combining drugs that target multiple neu APPLICATIONS rotransmitter systems or genes is perhaps more important to the development of future pharmacotherapies for treatment of 0001. This application is entitled to priority pursuant to 35 alcohol dependence and treatment of other addictive disor U.S.C. S 119(e) to U.S. provisional patent application No. ders and impulse control disorders. 607898,527, filed on Jan. 31, 2007. The entire disclosure of 0006 Various medications and behavioral therapy have the afore-mentioned patent application is incorporated herein been used to treat alcohol dependence. The neuronal targets by reference. of alcohol include many neurotransmitter systems and the FIELD OF THE INVENTION molecules participating in or regulating the systems, includ ing GABA, glutamate, DA, opioids, and serotonin (for a 0002 The present invention relates generally to the use of review see Johnson, 2004, Expert Opin. Pharmacother. 5:9: combination therapies to treat addiction-related diseases and 1943-1955). disorders and impulse control disorders, particularly alcohol 0007. Despite the number of studies performed in this related diseases and disorders. area, few drugs for alcohol dependence are approved in the U.S. The approved drugs are disulfuram, naltrexone, Vivit BACKGROUND rex R/Vivitrol(R) (a long-acting depot formulation of naltrex 0003) Neuroscientific advances have increased greatly our one), and acamprosate. Disulfuram is an irreversible inhibitor understanding of the pharmaco-behavioral effects of various of aldehyde dehydrogenase leading to increased levels of neurotransmitter systems in the acquisition and maintenance acetaldehyde, a toxic intermediate in alcohol metabolism. of alcohol dependence. Medications that interact either Patients who take disulfuram and drink alcohol experience an directly or indirectly with neurotransmitters that modulate increased dilation of arterial and capillary tone producing cortico-mesolimbic dopamine (CMDA) neurons have been hypotension, nausea, vomiting, flushing, headache and pos central to most pharmacological strategies in the last decade. sibly in some, worse symptoms. Therefore, the concept Direct dopamine (DA) antagonists have failed to demonstrate behind the use of disulfuram is that the alcohol-dependent therapeutic efficacy consistently, possibly because the high individual associates drinking with unpleasant adverse events degree of neuroadaptation that occurs with direct post-Syn and, as a result, avoids further alcohol consumption. Never aptic blockade mitigates against any long-standing therapeu theless, recent research shows that disulfuram has limited tic effect. utility because compliance is low unless it is administered by 0004 Three major issues have promulgated scientific a partner or spouse. interest in the development of medicational adjuncts to psy 0008 Naltrexone's principal site of action is at the Lopioid chosocial or behavioral therapy for the treatment of alcohol receptors in the mesolimbic pathway, putatively blocking the ism. First, up to one-half of alcoholics relapse shortly after reinforcing effects of alcohol by decreasing DA release in the detoxification, psychosocial, or behavioral treatment. Sec nucleus accumbens (NAc). Studies using naltrexone report ond, advances in the neurosciences have implicated several that the opioid antagonist is more effective than placebo in target neurotransmitter systems such as those within the reducing craving and heavy drinking, and increasing the per mesocorticolimbic pathway which mediate some of alcohol's centage of non-drinking days, but does not necessarily rewarding effects associated with its abuse liability. Selective enhance abstinence. Although these studies Support the effi medications designed to oppose these neuronal systems may cacy of naltrexone, others report limited utility for the drug enhance the effectiveness of alcoholism treatments. Third, only when individuals were highly compliant or even not at Some alcoholics may possess biological abnormalities which all. predispose them to disease. These biologically-Vulnerable 0009 Acamprosate, a structural analogue of GABA, was alcoholics might benefit from specific adjunctive medication approved to promote abstinence in recently detoxified indi targeted towards correcting or ameliorating the underlying viduals. Although the exact mechanism of action is unknown, abnormalities. Since these abnormalities involve several neu the drug is thought to restore glutamatergic-mediated inhibi rotransmitters, combinations of medications targeting spe tory and excitatory neurotransmission in the NAc.
Recommended publications
  • Curriculum Vitae April 2013

    Curriculum Vitae April 2013

    Curriculum Vitae April 2013 NAME Michael Jeffrey Aminoff CONTACT Box 0114, Room 795-M, Dept of Neurology, 505 Parnassus Ave., San Francisco, CA 94143-0114 Tel: 415 353-1940; Fax 415 353-3289 [email protected] PLACE OF BIRTH England NATIONALITY British and US MARITAL STATUS Married, with three children CURRENT TITLE Endowed Chair in Parkinson’s Disease Research Distinguished Professor of Neurology & Executive Vice Chair, Department of Neurology, School of Medicine University of California, San Francisco Attending Physician (Neurologist) University of California Medical Center, San Francisco Director, Parkinson's Disease & Movement Disorders Clinic University of California Medical Center, San Francisco EDUCATION AND TRAINING EARLY EDUCATION Caterham School, Surrey, England MEDICAL SCHOOL University College, London, England, 1959-1962 University College Hospital, England, 1962-1965 QUALIFICATIONS 1962 B.Sc. Special (London) 1965 L.R.C.P., M.R.C.S., M.B., B.S. [Equivalent to MD degree in USA] 1968 M.R.C.P. (London) [Similar to Board Certification in Internal Medicine in USA] 1973 M.D. (London) [Advanced Research Thesis similar to Ph.D. in USA] 1976 Federal Licensing Examination and California Medical License 1977 Membership by examination, American Association of Electromyography & Electrodiagnosis, leading in 1989 to Certification by American Board of Electrodiagnostic Medicine. 1980 Certification by the American Board of Clinical Neurophysiology (ABQEEG) 1982 Certification in Neurology, American Board of Psychiatry & Neurology; recertified voluntarily, 2004 1984 F.R.C.P. (London) 1992 Subspecialty certification in Clinical Neurophysiology, American Board of Psychiatry & Neurology (new subspecialty); recertified 2002 1 2000 D.Sc. (London) [Higher doctorate in Faculty of Science, London University, London, UK] PRINCIPAL POSITIONS HELD 1965-1966 House physician & house surgeon, University College Hospital, London, U.K.
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Appendix 13C: Clinical Evidence Study Characteristics Tables

    Appendix 13C: Clinical Evidence Study Characteristics Tables

    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
  • Vascular Effects of Nitric Oxide the Relation to Migraine ISBN 90-9009713-9 NUGI 7411746

    Vascular Effects of Nitric Oxide the Relation to Migraine ISBN 90-9009713-9 NUGI 7411746

    Vascular effects of nitric oxide the relation to migraine ISBN 90-9009713-9 NUGI 7411746 Printing by: WRidderprint Offsetdrnkkerij b.v., Ridderkerk, The Netherlands © E.M. van Gelderen 1996 All rights reserved. Save exceptions by the law, no patt of this publication may be reproduced, stored in a retrieval system of any nature, or transmitted in any form or by means, electronic, mechanical, photocopying, recording or othenvise, including a complete or pattial transcription, without the prior written permission of the author, or where appropriate, of the publishers of the atticles. Vascular Effects of Nitric Oxide The Relation to Migraine De vasculaire effecten van stikstof oxide de relatie met migraine Proefschrift ter verkrijging van de graad van Doctor aan de Erasmus Universiteit Rotterdam op gezag van de Rector Magnificus Prof. Dr. P.W.C. AKKERMANS MA en volgens het besluit van het College van Promoties De openbare verdediging zal plaats vinden op woensdag 18 september 1996 om 11.45 uur door Eduard Marcel van Gelderen geboren te Rotterdam Promotiecommissie Promotor: Prof. Dr. P.R. Saxena Overige leden: Prof. Dr. AJ. Man in 't Veld Prof. Dr. F.P. Nijkamp Prof. Dr. P.D. Verdouw Prof. Dr. P.A. van Zwieten Dr. M.D. Ferrari Dr. P.l Koudstaal This thesis was prepared at the Department of Pharmacology of the Erasmus University Rotterdam, P.O.Box 1738, 3000 DR Rotterdam, The Netherlands Tel' nagedachtenis aan mijn vader Vaal' Saskia, Kimberley en Felix Table of contents page Chapter 1. General introduction 11 1.1 Pathophysiology of migraine 1.2 Local regulation of vascular tone; endothelium-derived factors 1.3 Aims of the thesis Chapter 2.
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe Et Al

    US 2011 01 05536A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0105536A1 Lewyn-Briscoe et al. (43) Pub. Date: May 5, 2011 (54) DOSING REGIMENASSOCATED WITH Publication Classification LONG-ACTING INUECTABLE PALIPERDONE ESTERS (51) Int. Cl. A 6LX 3/59 (2006.01) (76) Inventors: Peter H. Lewyn-Briscoe, A6IP 25/18 (2006.01) Newtown, PA (US); Cristiana Gassmann-Mayer, Pennington, NJ (US); Srihari Gopal, Belle Meade, (52) U.S. Cl. ................................................... S14/259.41 NJ (US); David W. Hough, Wallingford, PA (US); Bart M.M. Remmerie, Gent (BE); Mahesh N. (57) ABSTRACT Samtani, Flemington, NJ (US) The present application provides a method for treating (21) Appl. No.: 12/916,910 patients in need of psychiatric treatment, wherein said patient (22) Filed: Nov. 1, 2010 misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides Related U.S. Application Data a method for treating psychiatric patients in need of a Switch (60) Provisional application No. 61/256,696, filed on Oct. ing treatment to paliperidone palmitate in a Sustained release 30, 2009. formulation. Patent Application Publication May 5, 2011 Sheet 1 of 6 US 2011/O105536 A1 FIG. 1 First-Order PrOCeSS Cp V CL Central (2) Zero-Order PrOCeSS Patent Application Publication May 5, 2011 Sheet 2 of 6 US 2011/O105536 A1 FIG. 2 25mgeq 50mgeq m-100mde::::: Missed doSe On WK 4. Patient returns On WK5 Missed doSe On WK 4. Patient returns On WK 6 -8-4 O 4 8 12 16 2024 -8-4 O 4 8 12 1620 24 Missed doSe On WK 4.
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence

    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al

    (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak Et Al

    USOO9642912B2 (12) United States Patent (10) Patent No.: US 9,642,912 B2 Kisak et al. (45) Date of Patent: *May 9, 2017 (54) TOPICAL FORMULATIONS FOR TREATING (58) Field of Classification Search SKIN CONDITIONS CPC ...................................................... A61K 31f S7 (71) Applicant: Crescita Therapeutics Inc., USPC .......................................................... 514/171 Mississauga (CA) See application file for complete search history. (72) Inventors: Edward T. Kisak, San Diego, CA (56) References Cited (US); John M. Newsam, La Jolla, CA (US); Dominic King-Smith, San Diego, U.S. PATENT DOCUMENTS CA (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Santa Barbara, 5,602,183 A 2f1997 Martin et al. CA (US); Wade A. Hull, Kaysville, UT 5,648,380 A 7, 1997 Martin 5,874.479 A 2, 1999 Martin (US); Ngoc Truc-ChiVo, Longueuil 6,328,979 B1 12/2001 Yamashita et al. (CA) 7,001,592 B1 2/2006 Traynor et al. 7,795,309 B2 9/2010 Kisak et al. (73) Assignee: Crescita Therapeutics Inc., 8,343,962 B2 1/2013 Kisak et al. Mississauga (CA) 8,513,304 B2 8, 2013 Kisak et al. 8,535,692 B2 9/2013 Pongpeerapat et al. (*) Notice: Subject to any disclaimer, the term of this 9,308,181 B2* 4/2016 Kisak ..................... A61K 47/12 patent is extended or adjusted under 35 2002fOOO6435 A1 1/2002 Samuels et al. 2002fOO64524 A1 5, 2002 Cevc U.S.C. 154(b) by 204 days. 2005, OO 14823 A1 1/2005 Soderlund et al. This patent is Subject to a terminal dis 2005.00754O7 A1 4/2005 Tamarkin et al.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al

    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.